Skip to main content

An evaluation of HIB vaccination and description of risk factors for HIB vaccine failure in Europe


- To obtain comparable estimates of age-specific vaccine efficacy of Hib vaccine in countries using different vaccines and schedules
- To describe the risk factors associated with vaccine failure using different vaccines and schedules

During the past decade, conjugate vaccines against Haemophilus influenzae type b (Hib) infection have been introduced into several countries in Europe for routine use in infants. Currently, the vaccination programmes in these countries differ with respect to the choice of vaccine, the schedule for primary immunisation, and the use of a booster dose in the second year of life. By describing and comparing the epidemiology of Hib disease in several countries, the relative effectiveness of Hib vaccine programmes will be compared. This will inform future vaccination policy and priorities for surveillance. In addition, pooling of data on Hib vaccine failures from several countries will be performed to describe risk factors for vaccine failure, and to allow comparison of these risk factors in different populations and with different vaccines and schedules. This data could lead to changes in recommendations for vaccination of high risk groups or contribute to the choice of appropriate vaccine programme for all children.


61,Colindale Avenue 61
NW9 5EQ London
United Kingdom